Workflow
麦澜德: 南京证券股份有限公司关于南京麦澜德医疗科技股份有限公司增加2025年度日常关联交易额度预计的核查意见
Zheng Quan Zhi Xing·2025-08-26 13:13

Core Viewpoint - The company, Nanjing Mairande Medical Technology Co., Ltd., is increasing its estimated daily related party transaction limit for 2025 to RMB 8 million, which is deemed necessary for its business development and complies with fair market practices [1][2][5] Group 1: Daily Related Party Transactions - The increase in the estimated daily related party transaction limit is approved by the board of directors and the supervisory board, confirming that it aligns with the company's operational needs and does not harm the interests of shareholders, especially minority shareholders [2][5] - The estimated amount for the increased daily related party transactions is RMB 8 million, which includes sales of goods and acceptance of services from related parties [2][4] - The company has established a good cooperative relationship with the related parties, ensuring that the transactions will continue to exist as long as the company's operations remain stable [4][5] Group 2: Pricing and Fairness - The pricing for the related party transactions is based on fair, open, and just principles, with market prices serving as the basis for negotiations [4] - The company has followed the necessary approval procedures as per its articles of association and relevant regulations, ensuring that the transactions do not adversely affect its independence or financial status [5] - The company will continue to avoid unnecessary related party sales, maintaining a low proportion of recurring related transactions to safeguard its independence [4][5] Group 3: Financial Impact - The related party transactions are expected to have no significant adverse impact on the company's financial condition or operational results, and the main business will not become dependent on these transactions [5]